MyoKardia (MYOK) Reports Q2 Loss of $0.37/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
MyoKardia Reports Second Quarter 2016 Financial Results and Continued Progress on Clinical Programs
August 9, 2016 8:31 AM EDTMYK-461 Phase 2 PIONEER-HCM Study to Initiate in Second Half of 2016
Clinical Program Builds on Positive Topline Results from Phase 1 Trials of MYK-461 in HCM
MYK-461 Development Program, Product Pipeline and Platform Focus of MyoKardia R&D Day on Sept. 21 in New York
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today reported business... More
